PEDEvidence
Latest studiesAll common questions
BASICS & PRODUCT QUALITY · COMMON QUESTIONS

Can an IGF-1 result prove that HGH is genuine and correctly dosed?

A blood response measures your biology, not the full contents of a vial.

Evidence at a glanceIGF-1 helps assess GH activity; it is not a product-quality certificate

An increase in IGF-1 can support the conclusion that the GH pathway has been stimulated, but it cannot verify every feature of a vial. It does not establish the exact amount, identity of all ingredients, sterility, or absence of contaminants. A biological response and an analytical product test answer different questions.[1]

IGF-1 is also influenced by the person being tested. Age, nutritional status, liver disease, and other clinical factors affect interpretation; low IGF-1 does not always mean GH deficiency. Comparing two users’ numbers without considering those differences is therefore a poor way to rank products or calculate a dose conversion.[1]

For medically prescribed GH, clinicians interpret age-adjusted IGF-1 alongside the diagnosis, symptoms, and adverse effects. Higher is not automatically better. Product quality requires reliable manufacturing and appropriate analytical checks, while treatment response requires clinical interpretation. Neither can safely substitute for the other.[1][2]

Sources & further reading

  1. Endocrine Society: growth hormone deficiency and interpreting IGF-1
  2. Genotropin prescribing information: adult monitoring and adverse effects

Updated September 24, 2026 · Evidence summaries for understanding research.

Q&A episodes behind this question

This question draws on the following public Q&A topics. The answer above is independently researched and does not quote or represent either creator’s advice.